WCN26-3746 Clinical Efficacy of Budesonide Enteric-Coated Capsules in the Treatment of IgA nephropathy with subclassication of focal segmental glomerulosclerosis and Analysis of Influencing Factors

Read full text Summarise with VIRAT
Authors: Shu Rong
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

To investigate the clinical efficacy of budesonide enteric-coated capsules (trade name: Naifukang) in patients with subclassication of focal segmental glomerulosclerosis of immunoglobulin A nephropathy (IgAN), and to analyze the impacts of baseline renal function, pathological features, and comorbid metabolic diseases on therapeutic outcomes, so as to provide evidence for individualized treatment.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106204–106204
Publication date
25 March 2026
Language
EN